Peptide‐Decorated Liposomes Enhance Fungal Targeting and Antifungal Drug Delivery
Source abstract
Abstract
Abstract Candida infections are a clinical challenge due to a limited repertoire of antifungal drugs, biofilm development, and antifungal drug resistance. Fungi‐targeted liposomes can improve antifungal drug solubility and delivery while reducing toxicity by enhancing fungal cell interaction. Here, liposomes that encapsulate the antifungal drug, posaconazole (POS), are decorated with the peptide, penetratin (Pen). Liposome‐fungal cell interaction increases significantly from ∼50% to >80% upon Pen conjugation with both C. albicans and C. auris . Pen‐decorated liposomes containing POS inhibit planktonic C. albicans and C. auris at liposome concentrations up to 8× lower than non‐Pen‐decorated liposomes, suggesting enhanced POS delivery due to increased fungal targeting. Furthermore, Pen‐decorated liposomes inhibit C. albicans and C. auris biofilm formation at POS concentrations that are up to 1300× lower than free POS. Finally, Pen‐decorated liposomes exhibit promising prophylactic activity in an intradermal C. albicans murine infection model, reducing fungal burden by ∼60% compared to non‐targeting POS‐loaded liposomes. Overall, Pen‐decorated, POS‐loaded liposomes expand the antifungal drug repertoire against Candida spp. and serve as a platform technology to improve the treatment of fungal infections.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Antimicrobial Peptides and Activities · Advanced biosensing and bioanalysis techniques · Supramolecular Self-Assembly in Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Engineering, Institute for Biology, Engineering, and Medicine Brown University Providence RI 02912 USA
Division of Biology and Medicine Brown University Providence RI 02912 USA
Funding
National Science Foundation
References (82)
Show source-provided references
1. N. R.Arya N. B.Rafiq Candidiasis inStatPearls [Internet].StatPearls Publishing 2023.
2. 10.1186/s13054-023-04673-610.1186/s13054-023-04673-6 ↗
3. 10.1016/j.rmcr.2015.03.00110.1016/j.rmcr.2015.03.001 ↗
4. 10.3390/antibiotics1208127710.3390/antibiotics12081277 ↗
5. 10.3390/jof601001610.3390/jof6010016 ↗
6. Spampinato C. · Biomed Res. Int. · 2013 · 2013
7. 10.1007/s40588-023-00190-w10.1007/s40588-023-00190-w ↗
8. 10.1146/annurev-micro-091014-10433010.1146/annurev-micro-091014-104330 ↗
9. Denning D. W. · Lancet Infect. Dis. · 2024
10. 10.1101/cshperspect.a01977810.1101/cshperspect.a019778 ↗
11. 10.3390/jof907072610.3390/jof9070726 ↗
12. 10.1016/j.mycmed.2017.12.00810.1016/j.mycmed.2017.12.008 ↗
13. 10.1053/jhin.2001.115110.1053/jhin.2001.1151 ↗
14. World Health Organization 2022.
15. 10.3390/microorganisms802018110.3390/microorganisms8020181 ↗
16. Center for Disease Control and Prevention 2019.
17. 10.3390/metabo1003010610.3390/metabo10030106 ↗
18. 10.1093/mmy/myz01210.1093/mmy/myz012 ↗
19. 10.3389/fmed.2018.0002810.3389/fmed.2018.00028 ↗
20. 10.1021/acsami.9b2070810.1021/acsami.9b20708 ↗
21. 10.3390/ijms2407661510.3390/ijms24076615 ↗
22. 10.1016/j.addr.2021.11385110.1016/j.addr.2021.113851 ↗
23. 10.3389/fbioe.2021.70588610.3389/fbioe.2021.705886 ↗
24. 10.2147/IJN.S6886110.2147/IJN.S68861 ↗
25. Nsairat H. · Heliyon · 2022
26. 10.1186/1556-276X-8-10210.1186/1556-276X-8-102 ↗
27. 10.3390/pharmaceutics1211105410.3390/pharmaceutics12111054 ↗
28. 10.1016/j.jddst.2023.10485410.1016/j.jddst.2023.104854 ↗
29. 10.3390/molecules2607204710.3390/molecules26072047 ↗
30. 10.1021/acsomega.3c0489310.1021/acsomega.3c04893 ↗
31. 10.1016/j.colsurfb.2015.12.00310.1016/j.colsurfb.2015.12.003 ↗
32. 10.1002/jbm.a.3698410.1002/jbm.a.36984 ↗
33. 10.1007/s11046-014-9837-210.1007/s11046-014-9837-2 ↗
34. 10.1049/mnl.2014.019810.1049/mnl.2014.0198 ↗
35. 10.1080/10717544.2018.149204610.1080/10717544.2018.1492046 ↗
36. 10.1002/jbm.a.3750110.1002/jbm.a.37501 ↗
37. 10.1111/jam.1505310.1111/jam.15053 ↗
38. 10.3389/fphar.2019.0140110.3389/fphar.2019.01401 ↗
39. 10.1016/j.jiac.2015.05.00710.1016/j.jiac.2015.05.007 ↗
40. 10.1007/s10571-023-01443-410.1007/s10571-023-01443-4 ↗
41. 10.1203/PDR.0b013e3181d601c510.1203/PDR.0b013e3181d601c5 ↗
42. Ambati S. · MSphere · 2019 · 4
43. 10.3390/ijms2403264310.3390/ijms24032643 ↗
44. 10.3390/pharmaceutics1404082110.3390/pharmaceutics14040821 ↗
45. 10.1016/j.jconrel.2020.04.01010.1016/j.jconrel.2020.04.010 ↗
46. 10.1063/5.002986010.1063/5.0029860 ↗
47. 10.1016/j.coph.2008.06.00210.1016/j.coph.2008.06.002 ↗
48. 10.1128/AAC.01199-0710.1128/AAC.01199-07 ↗
49. 10.1002/pro.320310.1002/pro.3203 ↗
50. 10.1016/j.jddst.2022.10349110.1016/j.jddst.2022.103491 ↗
51. 10.1021/acs.cgd.9b0102610.1021/acs.cgd.9b01026 ↗
52. Chang M. · Pharm. Therap. · 2008 · 33 · 391
53. 10.3389/fmicb.2016.0217310.3389/fmicb.2016.02173 ↗
54. 10.1111/apm.1333610.1111/apm.13336 ↗
55. Carrillo‐Muñoz A. J. · Revista Espanola de Quimioterapia · 2010 · 23 · 3
56. 10.2147/TCRM.S332910.2147/TCRM.S3329 ↗
57. 10.1586/17512433.2015.103468910.1586/17512433.2015.1034689 ↗
58. 10.1021/acs.langmuir.6b0074110.1021/acs.langmuir.6b00741 ↗
59. 10.1016/j.fct.2018.01.01710.1016/j.fct.2018.01.017 ↗
60. 10.1073/pnas.200480711710.1073/pnas.2004807117 ↗
61. 10.3389/fmicb.2019.0299310.3389/fmicb.2019.02993 ↗
62. 10.1128/MMBR.00032-0710.1128/MMBR.00032-07 ↗
63. 10.3389/fimmu.2017.0062910.3389/fimmu.2017.00629 ↗
64. 10.1021/mp300097k10.1021/mp300097k ↗
65. Jacobs S. E. · Antimicrob. Agents Chemother. · 2022 · 66
66. 10.3389/fmicb.2021.63860910.3389/fmicb.2021.638609 ↗
67. 10.1007/s40588-020-00143-710.1007/s40588-020-00143-7 ↗
68. 10.2217/fmb.13.10110.2217/fmb.13.101 ↗
69. 10.3934/microbiol.2018.2.27410.3934/microbiol.2018.2.274 ↗
70. 10.1074/jbc.R116.72099510.1074/jbc.R116.720995 ↗
71. 10.1128/AAC.00946-1310.1128/AAC.00946-13 ↗
72. 10.3389/fcimb.2019.0047110.3389/fcimb.2019.00471 ↗
73. 10.1016/j.micinf.2016.01.00210.1016/j.micinf.2016.01.002 ↗
74. 10.1128/AAC.43.4.76310.1128/AAC.43.4.763 ↗
75. 10.1186/s12985-024-02519-310.1186/s12985-024-02519-3 ↗
76. 10.1038/s41598-019-42456-810.1038/s41598-019-42456-8 ↗
77. 10.3389/fphar.2015.0028610.3389/fphar.2015.00286 ↗
78. 10.1080/17425255.2020.176493910.1080/17425255.2020.1764939 ↗
79. Ianas V. · Infect Drug Resist. · 2010 · 45
80. Bailey‐Hytholt C. M. · J. Visual. Experim. · 2021 · 174
81. 10.1002/adhm.20240115710.1002/adhm.202401157 ↗
82. Santus W. · J. Vis. Exp. · 2018